Author Archives : Editorial Team

Home  >>  Author : Editorial Team

Merck: FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

On January 8, 2018, Posted by , In News, With Comments Off on Merck: FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage1,2 Javelin Renal clinical development program is ongoing, including Phase III first-line study Darmstadt, Germany, and New York, US, December 21, 2017 – Merck and…

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

On January 8, 2018, Posted by , In News, With Comments Off on Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card…

BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection

On January 8, 2018, Posted by , In News, With Comments Off on BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection

Innsbruck, Austria – January 3rd, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, announced today the acquisition of Metanomics Health GmbH. Metanomics Health is a metabolomics biomarker development and healthcare services specialist based in Berlin, Germany. At the same time, the company is closing a significant…

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

On January 8, 2018, Posted by , In News, With Comments Off on Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

New partnership will focus on discovering and developing novel treatment options for Crohn’s disease and Ulcerative colitis Orally available novel Locked Nucleic Acid (LNA) oligonucleotides technology at the core Ingelheim, Germany – 19 December, 2017 – Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and…

DKFZ: Levels of DNA tags characterize rare type of blood cancer

On January 8, 2018, Posted by , In News, With Comments Off on DKFZ: Levels of DNA tags characterize rare type of blood cancer

Not only genetic changes but also certain DNA tags play a role in the development of cancer. Scientists at the German Cancer Research Center (DKFZ) have discovered that leukemia of a specific type is extremely difficult to treat if the cancer cells contain very high levels of a certain type…

Logistik- und SAP-Kompetenz aus einer Hand: ParCon wird Teil von io-consultants

On January 8, 2018, Posted by , In News, With Comments Off on Logistik- und SAP-Kompetenz aus einer Hand: ParCon wird Teil von io-consultants

Heidelberg, 02.01.2018. Seit 1. Januar 2018 ist der SAP-Experte ParCon Consulting mit seinen Niederlassungen in Leonberg/Stuttgart und Berlin Teil des Beratungs- und Planungsunternehmens io-consultants mit Hauptsitz in Heidelberg. io-consultants baut dadurch seine Kompetenzen im Bereich SAP-Beratung aus und setzt ein deutliches Signal für weiteres Wachstum. Schon heute vereint io-consultants als…

DKFZ:Molecular super enhancers: A new key for targeted therapy of brain cancer in children

On December 31, 2017, Posted by , In News, With Comments Off on DKFZ:Molecular super enhancers: A new key for targeted therapy of brain cancer in children

Ependymoma refers to a heterogeneous group of cancers that can occur at any age and is one of the most common types of brain cancer in children. The genetic causes for its development are largely unknown and there are no targeted treatments to date. Scientists from the “Hopp Children’s Cancer…

Roche: FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer

On December 31, 2017, Posted by , In News, With Comments Off on Roche: FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has approved Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast…

Roche: European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

On December 31, 2017, Posted by , In News, With Comments Off on Roche: European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSCLC Approval based on phase III ALEX data showing Alecensa reduced the risk of disease progression or death by more than half versus crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has…

BioRN Network e.V. members assembly 2017: Entering a new era of excellence

On December 18, 2017, Posted by , In News, With Comments Off on BioRN Network e.V. members assembly 2017: Entering a new era of excellence

Heidelberg (D)|The BioRN Network e.V. members came together on December 11th, 2017 to set the future path for the BioRN Network. The decisions made during the members assembly emanate from extensive work on the thematic focus, strategy and composition of the cluster over the past year. Together with the elections…